Skip to main content
SpringerLink
Log in
Book cover

Cardiovascular Endocrinology pp 199–215Cite as

Sexual Dysfunction and Cardiovascular Risk – Links and Solutions

  • Chapter

  • 713 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Summary

Erectile dysfunction (ED) is an increasingly common problem, affecting up to 30 million men in the US and 140 million men worldwide. The prevalence and incidence of ED is closely related to an aging population and also to an increase in other associated risk factors (such as type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, smoking and polypharmacy). Several of these risk factors for ED are also components of the metabolic syndrome. The metabolic syndrome refers to a clustering of established and emerging cardiovascular (CV) risk factors within a single individual. The diagnosis of the metabolic syndrome in an individual increases the risk of subsequent cardiovascular disease (CVD) approximately twofold and T2DM fivefold. Endothelial dysfunction is a major unifying etiology for many of the aspects of the metabolic syndrome, especially T2DM and CVD. It also plays a major role in ED. In fact, the presentation of ED should alert the physician to an underlying CV problem particularly in a patient with T2DM. This should lead to screening for CV risk factors and appropriate risk stratification for asymptomatic men with ED. Men with ED and other CV risk factors should be counseled in lifestyle modification, and treated where indicated with agents aimed at reducing CV risk (i.e., statins, aspirin, antihypertensives, etc). Treatment of ED in general and in men with diabetes has been revolutionized with the introduction of phosphodiesterase type 5 (PDE5) inhibitors. However, men with diabetes tend to respond less well to these agents. This decreased responsiveness may relate to the severity of ED in diabetes. Alternative therapeutic strategies may be needed to overcome this problem. The safety of PDE5 inhibitors in men with ED and concomitant CVD seems to be generally accepted, especially when these agents are used according to the respective prescribing information and as per current guidelines.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

    Google Scholar 

  2. Selvin E, Burnett AL, Platz EA: Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151–157.

    Article  PubMed  Google Scholar 

  3. Matfin G, Jawa A, Fonseca VA: Erectile dysfunction: interrelationship with the metabolic syndrome. Curr Diab Rep 2005; 5: 64–69.

    Article  PubMed  CAS  Google Scholar 

  4. Matfin G: Diabetes mellitus and the metabolic syndrome. In: Porth CM, ed. Essentials of Pathophysiology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:987–1015.

    Google Scholar 

  5. Rosen RC, Jackson G, Kostis JB: Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7: 490–496.

    Article  PubMed  Google Scholar 

  6. Matfin G: New treatments for erectile dysfunction. Fertil Steril 2003; 80 Suppl 4: 40–45.

    Article  PubMed  Google Scholar 

  7. Vardi M, Nini A: Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002187. DOI: 10.1002/14651858.CD002187.pub3.

    Google Scholar 

  8. Matfin G: Disorders of the male genitourinary system. In: Porth CM, ed. Essentials of Pathophysiology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:901–923.

    Google Scholar 

  9. Lue TF: Erectile dysfunction. N Eng J Med 2000; 342: 1802–1813.

    Article  CAS  Google Scholar 

  10. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  11. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.

    Article  PubMed  Google Scholar 

  12. Fonseca VA: Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000;133:154–156.

    PubMed  CAS  Google Scholar 

  13. Fonseca V, Desouza C, Asnani S, Jialal I: Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 2004; 25:153–175.

    Article  PubMed  CAS  Google Scholar 

  14. Stern MP: Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995; 44:369–374.

    Article  PubMed  CAS  Google Scholar 

  15. Heidler S, Temml C, Broessner C: Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007; 177: 651–654.

    Article  PubMed  Google Scholar 

  16. Kupellian V, Shabsigh R, Arujo AB, et al.: Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222–226.

    Article  Google Scholar 

  17. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    PubMed  CAS  Google Scholar 

  18. Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788–791.

    Article  PubMed  CAS  Google Scholar 

  19. Gkaliagkousi E, Shah A, Ferro A: Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes. Br J Diabetes Vasc Dis 2007; 7:5–10.

    Article  CAS  Google Scholar 

  20. Matfin G, Jawa A, Fonseca VA: Erectile dysfunction in diabetes: an endothelial disorder. In: Fonseca V, ed. Clinical Diabetes: Translating Research into Practice. Philadelphia, PA: Saunders, 2006:165–178.

    Google Scholar 

  21. Pegge NC, Twomey AM, Vaughton K, et al.: The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med 2006; 23:873–878.

    Article  PubMed  CAS  Google Scholar 

  22. Theuma P, Fonseca VA: Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes. Curr Drug Targets 2003; 4: 477–486.

    Article  PubMed  CAS  Google Scholar 

  23. Baron AD: Insulin resistance and vascular function. J Diabetes Complicat 2002; 16: 92–102.

    Article  PubMed  Google Scholar 

  24. Baron AD: Insulin and the vasculature – old actors, new roles. J Invest Med 1996; 44:406–412.

    CAS  Google Scholar 

  25. Grover A, Padginton C, Wilson MF, et al. Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension 1995; 25:779–784.

    PubMed  CAS  Google Scholar 

  26. Aljada A, Dandona P: Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000; 49:147–150.

    Article  PubMed  CAS  Google Scholar 

  27. Aljada A, Ghanim H, Assian E, Dandona P: Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 2002; 51:487–491.

    Article  PubMed  CAS  Google Scholar 

  28. Zeng G, Quon MJ.: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98:894–898.

    Article  PubMed  CAS  Google Scholar 

  29. Caballero AE, Arora S, Saouaf R, et al.: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48:1856–1862.

    Article  PubMed  CAS  Google Scholar 

  30. De Angelis L, Marfella MA, Siniscalchi M, et al.: Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 2001; 44:1155–1160.

    Article  PubMed  Google Scholar 

  31. Esposito K, Giugliano F, Di Palo C, et al.: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978–2984.

    Article  PubMed  CAS  Google Scholar 

  32. Chan NN, Chan JC.: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002, 45: 1609–1616.

    Google Scholar 

  33. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420–1426.

    Article  PubMed  Google Scholar 

  34. Mass R, Schwedhelm E, Albsmeier J, Boger RH: The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213–225.

    Article  Google Scholar 

  35. Masuda H, Tsujii T, Okuno T, et al.: Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1730–R1738.

    PubMed  CAS  Google Scholar 

  36. Cartledge JJ, Eardley I, Morrison JF: Impairment of corpus cavernosal smooth muscle relaxation by glycosylated human haemoglobin. BJU Int 2000, 85: 735–741.

    Article  PubMed  CAS  Google Scholar 

  37. Fonseca V, Seftel A, Denne J, Fredlund P: Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004; 47:1914–1923.

    Article  PubMed  CAS  Google Scholar 

  38. Veves A, Akbari CM, Primavera J, et al.: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457–463.

    Article  PubMed  CAS  Google Scholar 

  39. Ross R: Atherosclerosis – an inflammatory disease. N Eng J Med 1999; 340:115–126.

    Article  CAS  Google Scholar 

  40. Billups KL, Kaiser DR, Kelly AS et al.: Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003; 15:231–236.

    Article  PubMed  CAS  Google Scholar 

  41. Blans MCA, Visseran FLJ, Banga JD et al.: Infection induced inflammation is associated with erectile dysfunction in men with diabetes. Eur J Clin Invest 2006; 36: 497–502.

    Article  PubMed  CAS  Google Scholar 

  42. Bacon CG, Mittleman MA, Kawachi I, et al.: Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139:161–168.

    PubMed  Google Scholar 

  43. Walczak MK, Lokhandwala N, Hodge MB, Guay AT.: Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5:19–24.

    PubMed  Google Scholar 

  44. Chung WS, Sohn JH, Park YY.: Is obesity an underlying factor in erectile dysfunction? Eur Urol 1999; 36: 68–70.

    Article  PubMed  CAS  Google Scholar 

  45. Derby CA, Mohr BA, Goldstein I, et al.: Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56(2):302–306.

    Article  PubMed  CAS  Google Scholar 

  46. Wei M, Macera CA, Davis DR, et al.: Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994, 140: 930–937.

    PubMed  CAS  Google Scholar 

  47. Gazzaruso C, Giordanetti S, De Amici E, et al.: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22–26.

    Article  PubMed  Google Scholar 

  48. Wackers FJ, Young LH, Inzucchi SE, et al.: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study. Diabetes Care 2004; 27:1954–1961.

    Article  PubMed  Google Scholar 

  49. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z: Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997, 9: 123–126.

    Article  PubMed  CAS  Google Scholar 

  50. Russell ST, Khandheria BK, Nehra A: Erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2004, 79: 782–794.

    Article  PubMed  Google Scholar 

  51. Jackson G: Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection. Drugs 2004, 64: 1533–1545.

    Article  PubMed  CAS  Google Scholar 

  52. Fink HA, Mac DR, Rutks IR, et al.: Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002, 162: 1349–1360.

    Article  PubMed  CAS  Google Scholar 

  53. Guay AT, Perez JB, Velasquez E, et al.: Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol 2000; 38: 671–676.

    Article  PubMed  CAS  Google Scholar 

  54. Carson CC, Burnett AL, Levine LA, Nehra A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12–27.

    Article  PubMed  Google Scholar 

  55. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–1336.

    Article  PubMed  CAS  Google Scholar 

  56. Saenz dT, Anglin G, Knight JR, Emmick JT.: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25:2159–2164.

    Article  Google Scholar 

  57. Porst H, Rosen R, Padma-Nathan H, et al.: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.

    Article  PubMed  CAS  Google Scholar 

  58. Gruenwald I, Shenfield O, Chen J, et al.: Positive effects of counseling and dose adjustment in patients with erectile dysfunction who had failed treatment with sildenafil. Eur Urol 2006; 50: 134–140.

    Article  PubMed  CAS  Google Scholar 

  59. Cheitlin MD, Hutter AM, Jr., Brindis RG, et al.: Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99: 168–177.

    PubMed  CAS  Google Scholar 

  60. DeSouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336–1339.

    Article  PubMed  CAS  Google Scholar 

  61. Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–851.

    Article  PubMed  CAS  Google Scholar 

  62. Halcox JP, Nour KR, Zalos G, et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232–1240.

    Article  PubMed  CAS  Google Scholar 

  63. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346:393–403.

    Article  CAS  Google Scholar 

  64. Esposito K, Di Palo C, Marfella R, Giugliano D: The effect of weight loss on endothelial functions in obesity: response to Sciacqua et al. Diabetes Care 2003; 26:2968–2969.

    Article  PubMed  Google Scholar 

  65. Esposito K, Pontillo A, Di Palo C, et al.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799–1804.

    Article  PubMed  CAS  Google Scholar 

  66. Saigal CS.: Obesity and erectile dysfunction: common problems, common solution? JAMA 2004; 291:3011–3012.

    Article  PubMed  CAS  Google Scholar 

  67. Saltzman EA, Guay AT, Jacobson J: Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255–258.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Glenn Matfin BSc (Hons), M.B. Ch.B., DGM, FFPM, FACE, FACP, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tulane University Health Sciences Center, New Orleans, LO, USA

    Vivian A. Fonseca (MD) (MD)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Matfin, G. (2009). Sexual Dysfunction and Cardiovascular Risk – Links and Solutions. In: Fonseca, V.A. (eds) Cardiovascular Endocrinology. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-141-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-141-3_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-850-8

  • Online ISBN: 978-1-59745-141-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation